Showing 742 results
-
Press release /Novartis COVID-19 Response Fund will provide grants of up to USD 1 million to support communities around the world most impacted by the Coronavirus outbreak Novartis to join collaborative R…
-
Press release /New data from the Phase 3 ASCLEPIOS I/II trials and ALITHIOS open-label extension show that after four years nearly 8 out of 10 of people with relapsing multiple sclerosis (RMS) treated continuously…
-
Press release /Jakavi is the first JAK1/2 inhibitor available for patients in Europe who previously had no approved therapies for the treatment of steroid-refractory graft-versus-host disease (GvHD)1,2 In clinical…
-
Press release /Novartis and Medicines for Malaria Venture (MMV) report positive Phase 2b study results for novel non-artemisinin combination to treat uncomplicated malariaIn the Phase 2b study conducted in children…
-
Ad hoc release /Ad-hoc-Mitteilung gemäss Art. 53 KR Der Nettoumsatz stieg im dritten Quartal um +5% (kWk¹, +6% USD) Die Division Innovative Medicines wuchs um +7% (kWk, +8% USD)Starke Performance der…
-
Press release /Approval is based on Phase III NATALEE data showing Kisqali® (ribociclib) plus adjuvant endocrine therapy (ET) demonstrated clinically meaningful invasive disease-free survival (iDFS) benefit in…
-
Clinical Trials /
-
Press release /Paul Hudson wird zum CEO, Novartis Pharmaceuticals, und Bruno Strigini zum CEO, Novartis Oncology, ernannt; David Epstein wird Novartis verlassen Paul Hudson und Bruno Strigini werden in…
-
Press release /Der Nettoumsatz (0% kWk[2]) bleibt im Gesamtjahr dank starker Performance der Wachstumsprodukte auf Vorjahresniveau Cosentyx (USD 1,1 Milliarden) erreicht Blockbuster-Status Entresto (USD 170…
-
Press release /Dank starker Performance der Wachstumsprodukte bleibt der Nettoumsatz im dritten Quartal (-1% kWk[2] und USD) weitgehend unverändert gegenüber dem Vorjahreszeitraum Gilenya (USD 790 Millionen, +…